Evaluating lung function in individuals with long-term effects of COVID-19
Quantitative Computed Tomography to Assess Ventilatory and Perfusion Abnormalities in Individuals With Post-Acute Sequelae of SARS-CoV-2 Infection
This study is trying to see how COVID-19 affects lung function in people who have ongoing symptoms, compared to those who didn’t have any symptoms.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | Tufts Medical Center Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT05866952 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess lung ventilation and perfusion defects in individuals suffering from Post-Acute Sequelae of SARS-CoV-2 (PASC). Participants with a history of COVID-19 and ongoing symptoms such as fatigue and dyspnea will undergo a series of tests, including pulmonary function tests and low-dose CT scans. The study will compare the lung function patterns of these individuals to asymptomatic controls to better understand the impact of COVID-19 on lung health.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a documented history of COVID-19 and persistent symptoms of fatigue or dyspnea.
Not a fit: Patients who have had a recent SARS-CoV-2 infection or those with significant pre-existing respiratory or cardiovascular conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of lung-related complications in COVID-19 survivors.
How similar studies have performed: Other studies have explored lung function in COVID-19 survivors, indicating a growing body of evidence on this topic, though this specific approach may offer novel insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 * Self-reported or documented SARS-CoV-2 infection by RT-PCR or Antigen testing \> 3 months ago or no previous history of SARS-CoV-2 infection (control group only) * Normal or mild abnormalities on baseline Pulmonary Function Tests (PFTs) * New or worsening symptoms of chronic fatigue, dyspnea or exercise intolerance after COVID-19 with otherwise unclear etiology (PASC group only) Exclusion Criteria: * SARS-CoV-2 infection by RT-PCR or Antigen testing within the last 3 months * Inability to provide consent or non-English speaking * Pregnancy * Any respiratory infection in last 4 weeks * PFT relative contraindications * History of major cardiovascular, pulmonary, renal, hepatic, autoimmune or neuromuscular disease including asthma, COPD, interstitial lung disease, heart failure, pulmonary arterial hypertension, or prior pulmonary embolism * Active malignancy undergoing treatment or history of malignancy involving the lung
Where this trial is running
Boston, Massachusetts
- Tufts Medical Center — Boston, Massachusetts, United States (Recruiting)
Study contacts
- Study coordinator: Bipin Malla
- Email: tuftsmccorstudy@tuftsmedicalcenter.org
- Phone: 617-636-6304
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.